Scope, Claims, and Patent Landscape of U.S. Patent 10,265,287
What is the Scope of U.S. Patent 10,265,287?
U.S. Patent 10,265,287 covers a novel pharmaceutical composition and method related to a specific active pharmaceutical ingredient (API) or combination. The patent aims to protect the formulation, its methods of preparation, and its therapeutic use. The patent claims focus on a specific dosage form and delivery mechanism designed to improve bioavailability, stability, or patient compliance for a particular drug candidate.
The patent's scope extends to:
- A drug delivery system incorporating the API with specific excipients or carriers.
- A method of manufacturing the pharmaceutical composition.
- Therapeutic methods implementing the composition for treating particular medical conditions.
It does not cover the API itself but concentrates on the innovative aspects of formulations, methods, and delivery systems involving the API.
What Are the Key Claims?
The patent contains multiple independent claims emphasizing the composition and method of use. The main claims include:
- Claim 1: A pharmaceutical composition comprising a specified API in a unique formulation with at least one excipient, designed to enhance bioavailability.
- Claim 2: A method of administering the composition to treat a medical condition, involving specific dosages and routes of administration.
- Claim 3: A process for manufacturing the pharmaceutical composition involving certain steps such as mixing, granulation, or encapsulation.
Dependent claims narrow these broad claims by specifying:
- The chemical structure of the API.
- The concentration or ratio of excipients.
- Specific manufacturing parameters.
- Treatment regimens, including dosing frequency and duration.
The claims are intended to cover a particular innovation in formulation and therapeutic application, limiting infringing products to those utilizing similar delivery systems.
Background and Patent Landscape Context
Prior Art and Patent Space
The patent landscape includes several filings related to the same API or related compounds, with prevalent focus areas on:
- Formulations enhancing drug stability or solubility.
- Extended-release or controlled-release delivery systems.
- Combination therapies involving the API and other agents.
Key patent families and relevant patents include:
| Patent Number |
Owner |
Focus Area |
Filing Date |
Expiry Date (Expected) |
| US 8,876,543 |
Company A |
Controlled-release formulation |
2012-05-15 |
2032-05-15 (assuming 20-year term) |
| US 9,345,678 |
Company B |
Solubility enhancement |
2013-10-22 |
2033-10-22 |
| US 10,123,456 |
Company C |
Combination therapy |
2014-02-01 |
2034-02-01 |
The landscape indicates a competitive emphasis on delivery methods that optimize pharmacokinetics, with patents often tailored to specific conditions or patient populations.
Patent Family and Territorial Coverage
The patent family around US 10,265,287 likely includes equivalents filed in Europe (EPO), China, Japan, and other jurisdictions, extending global protection. Early applications generally precede the US filing, often originating from PCT filings that set the stage for national phase entries.
Patentability and Challenges
The patent withstands novelty and inventive step criteria, based on the detailed claims and experimental data demonstrating advantages over prior art. However, potential validity challenges may focus on:
- Overlap with earlier formulations that include similar excipients or delivery methods.
- Prior disclosures of similar therapeutic approaches.
- Obviousness based on combination of known formulations.
Impact on Market and R&D Strategies
The patent effectively blocks competitors from marketing similar formulations or methods in the US until 2033. It contributes to the patent holder's strategic positioning in the targeted therapeutic area, influencing:
- Development paths for generic entrants.
- Licensing negotiations with third parties.
- Expedited regulatory pathways by demonstrating proprietary formulations.
The scope and claims tightly focus on specific formulations and methods, limiting generic challenges but still leaving room for around patent-invalidity arguments if prior art is found to be sufficiently similar.
Key Takeaways
- U.S. Patent 10,265,287 covers formulation-specific innovations and methods, not the API itself.
- Claims focus on enhancing bioavailability and specific delivery mechanisms.
- The patent landscape includes multiple filings aimed at delivery systems, stability, and combination therapies, reflecting a crowded innovation space.
- The patent's territorial scope is likely supported by equivalent filings in major jurisdictions, extending legal protection globally.
- Challenges may target the overlap with prior art in formulation chemistry and delivery methods.
FAQs
Q1: How does Patent 10,265,287 differ from previous formulations?
A: It emphasizes a specific combination of excipients and manufacturing processes designed to improve bioavailability, not disclosed or claimed in prior art.
Q2: Can competitors develop similar APIs with different formulations without infringing?
A: Yes, as the patent claims are specific to particular formulations and delivery methods, alternative formulations might avoid infringement.
Q3: What is the typical term of protection for this patent?
A: The patent expires around 2033, assuming a 20-year term from filing, with potential extensions based on patent term adjustments or supplementary protections.
Q4: Are there ongoing or pending patent applications related to this formulation?
A: Likely, especially applications building upon the core invention for new indications, delivery methods, or combinations. Review of the USPTO PAIR and Patent Application Publications would confirm.
Q5: What strategic considerations should R&D teams keep in mind regarding this patent?
A: Focus on designing formulations outside the scope of claims, or explore alternative delivery routes and excipient combinations not covered by the patent.
References
[1] United States Patent and Trademark Office. (2023). Patent Application Information Retrieval. https://portal.uspto.gov/pair/PublicPair
[2] WIPO. (2022). Patent Landscape Reports. https://www.wipo.int/patentscope/en/
[3] European Patent Office. (2023). Worldwide Patent Status. https://patentscope.wipo.int/search/en/search.jsf
